Publications describing the use of

Psoriasis Disability Index

1.      Finlay A Y, Kelly S E.  Psoriasis - An index of disability.  Clinical and Experimental Dermatology, 1987; 12: 8- 11.

2.      Finlay A Y, Khan GK, Luscombe D K, Salek M S.  Validation of sickness impact profile and Psoriasis Disability Index in psoriasis.  British Journal of Dermatology, 1990; 123: 751-756.

3.      Kent G, Al-Abadie M.  The Psoriasis Disability Index - further analyses.  Clinical and Experimental Dermatology, 1993; 18: 414-416.

4.      Salek M S, Finlay A Y.  Cyclosporin improves quality of life in psoriasis - does this matter?  British Journal of Dermatology, 1993; 129 (Suppl 42):32.

5.      Root S, Kent G, Al-Abadie M S K.  The relationship between disease severity, disability and psychological distress in patients undergoing PUVA treatment for psoriasis.  Dermatology, 1994; 189: 234-237.

6.      Finlay A Y.  Effect of cyclosporin A on quality of life in psoriasis and atopic eczema.  J Dermatol Treat 1995; 5 (Suppl 1): S13-S15.

7.      Finlay A Y, Coles EC.  The effect of severe psoriasis on the quality of life of 369 patients.  British Journal of Dermatology, 1995; 132: 236-244.

8.      Gledhill K, Keller-Jackson L, Cheeseborough M.  Clinical psychology liaison in a dermatology clinic: a demonstration project.   Presented at 6th International Congress on Dermatology and Psychiatry, Amsterdam.  The Netherlands, April 20th - 22nd, 1995.

9.      Haisma H H, Kaptein A A, Thio H B, Vermeer, B J.  Social aspects of psoriasis, the Psoriasis Disability Index.  Presented at 6th International Congress on Dermatology and Psychiatry, Amsterdam, The Netherlands, April 20th - 22nd, 1995.

10.  Parry E J, Tillman D M, Long J, MacKie R M.  Audit of UVB phototherapy in the treatment of psoriasis.  British Journal of Dermatology, 1995; 133 (Suppl 45): 16.

11.  O’Neill P, Kelly P.  Postal Questionnaire Study of Disability in the Community Associated with Psoriasis.  British Medical Journal, 1996; 313: 919-21.

12.  Nichol M B, Margoilies J E, Lippa E, Rowe M, Quell J.  The application of multiple quality of life instruments in individuals with mild-to-moderate psoriasis.  Pharmacoeconomics 1996; 10: 644-653.

13.  Oakley A M, Wyllie K.  A review of ultraviolet treatment for psoriasis at Waikato Hospital.  Australas J Dermatol 1996; Aug 37(3): 132-136.

14.  Finlay A Y.  Quality of life measurement in dermatology: a practical guide.  Br J Dermatol, 1997; 136: 305-314.

15.  Finlay A Y. The outcomes movement and new measures of psoriasis.  J Am Acad Dermatol, 1997; 36: 502-503.

16.  Finlay A Y.  Evaluation of quality of life in dermatology: application to psoriasis.  Chapter in “Epidemiology, Cause and Prevention of Skin Diseases”.  Editors: Grob J J, Stern R S, Mackie R M, Weinstock W A.  Blackwell Scientific, Oxford, 1997.

17.  Fortune D G, Main C J, O’Sullivan TM, Griffiths C E M.  Quality of Life in Patients with Psoriasis: The Contribution of Clinical Variables and Psoriasis-Specific Stress.  British Journal of Dermatology, 1997; 137: 755-760.

18.  Poyner T F, Menday A P.  Quality of life measurement in general practice plaque psoriasis patients.  British Journal of Dermatology, 1998; 138: 376.

19.  Gupta G, Long J, Tillman D M.  Audit of narrowband UVB phototherapy in the treatment of psoriasis.  British Journal of Dermatology, 1998; 139 (Suppl 1): 55.

20.  Wall A R J, Poyner T F, Menday A P.  A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis.  British Journal of Dermatology, 1998; 139: 1005-1011.

21.  Wahl A, Rustdon T, Hanestad B R.  The relationship between coping and quality of life aspects on patients with psoriasis.  Quality of Life Research 1998; 7: 671-672.

22.  Finlay A Y.  Quality of life and its measurement.  Chapter in “Key Advances in the Effective Management of Psoriasis”.  Editors: Griffiths C, Barker J.  Royal Society of Medicine Press, London, 1999.

23.  Gupta G, Long J, Tillman D M.  The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures.  British Journal of Dermatology, 1999; 140: 887-890.

24.  Wahl A, Moum T. Hanestad B R, Wiklund I.  The relationship between demographic and clinical variables, and quality of life aspects in patients with psoriasis.  Quality of Life Research 1999; 8 (4): 319-326..

25.  Wahl A, Hanestad B R, Wiklund I, Moum T..  Coping and quality of life in patients with psoriasis. Quality of Life Research 1999; 8(5): 427-433.

26.  Kirby B, Fortune D G, Bhushan M, Chalmers R J G, Griffiths C E M.  The Salford Psoriasis Index:  An holistic measure of psoriasis severity.  British Journal of Dermatology 2000; 142: 728-732

27.  Hutchinson P, Marks R, White J, Rollin T.  The efficacy, safety and tolerance of topical calcitriol 3 ug/g ointment in the treatment of plaque psoriasis; a comparison with short-contact dithranol.  J Eur Acad Dermatol Venereol 2000; 14 (Suppl 1):  259. 
ALSO:  Dermatology 2000; 201: 139-145.

28.  O’Leary C J, Weinman J, Higgins E Creamer D.  Beliefs about medication in psoriasis and their association with adherence.  Br J Dermatol 2001; 145 (Suppl 59): 40-76.

29.  Kirby B, Richards H L, Woo P et al.  Both physical and psychological measures are necessary to assess overall severity of psoriasis. Br J Dermatol 2001; 145 (Suppl 59): 40-76.

30.  Zachariae H, Zachariae R, Blomquist K, Davidsson S, Molin L, Mork C, Sigurgeisson B.  Quality of life and prevalence of arthritis among 5795 members of nordic psoriasis associations.  JEADV 2001; 15 (Suppl 2): 245.

31.  Finlay A Y, Corvest M, Lefrancois P, Taieb C.  The French version of the psoriasis disability index. JEADV 2001; 15 (Suppl 2): 250. 
ALSO Ann Dermatol Venereol 2002; 129: 1S755-6

32.  Finlay A Y, Corvest M, Lefrancois P, Taieb C.  Psoriasis and current life: preliminary results on 527 subjects.  JEADV 2001; 15 (Suppl 2): 244.

33.  Davidson S, Blomquist K, Molin L et al.  Lifestyle of 6497 nordic psoriasis patients. JEADV 2001; 15 (Suppl 2): 245.

34.  Dreno B, Finlay A Y, Corvest M et al.  Follow-up psoriasis-observation and therapy:  French initiative.  JEADV 2001; 15 (Suppl 2): 238.

35.  Kirby B, Richards H L, Woo P, Hindle E, Main CJ  , Griffiths C E.  Physical and psychological measures are necessary to assess overall psoriasis.  J Am Acad Dermatol 2001; 45(1): 72-76.

36.  Zachariae R, Zachariae H et al Quality of life in 6497 Nordic patients with psoriasis.  Br J Dermatol 2002; 146: 1006-1016

37.  Sivayathorn A.  Quality of life assessment in psoriasis.  Ann Dermatol Venereol 2002; 129: 1S12.

38.  D’Souza M Rakesh SV, Unni KES, Sahai A.  Quality of life in patients with psoriasis.  A preliminary study from South India. Ann Dermatol Venereol 2002; 129: 1S752.

39.  Finlay AY, Corvest M, Lefrancois P, Myon E, Taieb C.  Psoriasis and everyday life:  First results on 1,866 subjects. Ann Dermatol Venereol 2002; 129: 1S755.

40.  Van de Kerkhof P.  A fixed combination of calcipotriol/betamethasone dipropionate improves quality of life in patients with psoriasis vulgaris. Ann Dermatol Venereol 2002; 129: 1S769-770.

41.  Zedan H, Mostafa AO.  Assessment of quallty of life in patients with psoriasis in Upper Egypt. Ann Dermatol Venereol 2002; 129: 1S798.

42.  Zachariae H, Zachariae R, Blomquist K et al.  Quality of life and prevalence of arthritis reported by 5795 members of the Nordic Psoriasis Associations --data from the Nordic quality of life study.  Acta Derm Venereol 2002; 82: 108-13.

43.  Kirby B, Mason DL, Richards HL, Main CJ, Griffiths CEM.  Psychological distress and alcohol habits in patients with psoriasis.  Br J Dermatol 2002; 147(Suppl 62): 28-29.

44.  Schiffner R, Glock B, Landthaler M, Stolz.  Willingness-to-pay and time-trade-off:  are they sensitive to changes of quality of life in interventional studies? JEADV 2002; 16 (Suppl 1): 213.

45.  Van de Kerkhof P C M.  A fixed combination of calcipotriol/betamethasone dipropionate improves quality of life in patients with psoriasis vulgaris. JEADV 2002; 16 (Suppl 1): 276.

46.  Lecha M, Mirada A, Lopez S.  Influence of Tacalcitol on the quality of life of patients with psoriasis vulgaris in clinical practice.  JEADV 2002; 16 (Suppl 1):  286.

47.  Salonen S-H.  Large-scale European psoriasis patient quality of life survey. JEADV 2002; 16 (Suppl 1): 287.

48.  Finlay A Y, Corvest M, Lefrancois P, Myon E, Taieb C.  Psoriasis and everyday life:  first results on 1866 subjects. JEADV 2002; 16 (Suppl 1): 292.

49.  Dreno B, Finlay A Y, Corvest M, Lefrancois P, Myon E., Taieb C.  Psoriasis disability is related to length of history of psoriasis. JEADV 2002; 16 (Suppl 1):  292.

50.  Van de Kerkhof P C M.  A fixed combination of calcipotriol/betamethasone dipropionate improves quality of life in patients with psoriasis vulgaris.  Br J Dermatol 2002; 147: 1074.

51.  Jenner N, Campbell J, Plunkett A, Marks R.  Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia.  Australas J Dermatol 2002; 43(4): 255-61.

52.  Fortune D G, Richards H L, Main C J, Griffiths C E.  Patient’s strategies for coping with psoriasis.  Clin Exp Dermatol 2002; 27(3): 177-184.

53.  Fortune D G, Richards H L, Griffiths C E, Main C J.  Psychological stress, distress and disability in patients with psoriasis:  consensus and variation in the contribution of illness perceptions, coping and alexithymia.  Br J Clin Psychol 2002; 41 (Pt2): 157-74

54.  Thaci D, Brautigam M, Kaufmann, Weidinger G, Paul C, Christophers E.  Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis.  Dermatology 2002; 205: 383-388.

55.  Salek M S, Finlay A Y. Quality of Life in patients with severe psoriasis receiving cyclosporin: a multi-centre study J Applied Therapeutic Research 2003; 4: 3-10.

56.  Clatici Cuibotaru V, Giurcaneanu C, Nedelcu AI A, Iamandescu D, Buzatel R, Iamandescu I B.

Correlation between anxiety, depression and quality of life in patients with psoriasis.  (Corelaţii între anxietate, depressie şi calitatea vieţii bolnavii cu psoriazis) Dermato Venerol (Buc),2003 47: 291-296.

57.  Andreassi L, Giannetti A, Milani M; On behalf of The Scale Investigators Group.  Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis:  an open, multicentre, randomized, controlled, cross-over on 241 patients.  Br J Dermatol 2003; 148(1): 134-138

58.  Salonen S H.  EUROPSO psoriasis patient survey:  first results from 17 990 association members with psoriasis. JEADV 2003; 17 (Suppl 3): 38.

59.  Taieb C, Corvest M, Myon E.  Psoriasis, quality of life and depressive symptomatology:  French results. JEADV 2003; 17: 62.

60.  A Y Finlay, Del Molino J M, Conesa A, Myon E, Taieb C.  Psoriasis and quality of life: Spanish results. JEADV 2003; 17: 62.

61.  S Taniguchi et. al.  Nishi-nihon hifu 61(6),801-812(1999).

62.  Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstädter F, Landthaler M and Stolz W.  Willingness to pay and time trade-off:  sensitive to changes of quality of life in psoriasis patients.  Br J Dermatol  2003; 148: 1153-1160.

63.  Woo W K, Mckenna K E.  Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial.  Br J Dermatol 2003;  149(1): 146-150.

64.  Hernanz J M, Vanaclocha F, Puig L L, Dauden E, Escudero J, Ferrandiz C Febrer I.  Safety of cyclosporin in patients with psoriasis.  JEADV 2003; 17 (Suppl 3): 384.

65.  Febrer I, Vanaclocha F, Puig L L, Dauden E, Escudero J, Hernanz J M, Ferrandiz C, Badia X.  Quality of life in psoriatic patients treated with cyclosporine.  JEADV 2003; 17 (Suppl 3): 384.

66.  Myon E, Finlay A Y, Lefrancois P, Taieb C.  Duration of psoriasis and Quality of Life.  JEADV 2003; 17 (Suppl 3):376.

67.  Taieb C, Finlay A, Lefrancois P, Myon E.  Psoriasis and Quality of Life:  SPOT study results at 3 months.  JEADV 2003; 17 (Suppl 3):376.

68.  Taieb C, Finlay A, Lefrancois P, Myon E.  Quality of Life according to gender.  JEADV 2003; 17 (Suppl 3):375.

69.  Taieb C, Finlay A, Del Molino J, Consa A, Myon E.  Psoriasis and Quality of Life:  Spanish Results.  JEADV 2003; 17 (Suppl 3): 375.

70.  Mirada A, Lecha M, Barnes E, Lopez J S on behalf of CALYPSO Research Group.  Safety and effectivity of tacalcitol in the treatment of psoriasis vulgaris in young patients.   JEADV 2003; 17 (Suppl 3): 373.

71.  Lopez J S, Barnes E, Mirada A, Lecha M, on behalf of CALYPSO Research Group.  Quality of life and psoriasis:  Impact of tacalcitol treatment.   JEADV 2003; 17 (Suppl 3): 373.

72.  Taieb C, Myon E.  Psoriasis:  cross-description of French and Spanish patients’ quality of life.  JEADV 2003; 17 (Suppl 3): 367.

73.  Garrido J, Myon E, Conesa A, Taieb C.  Psoriasis:  impact of the treatment on quality of life, Spanish results.  JEADV 2003; 17 (Suppl 3): 367.

74.  Myon E, Finlay A Y, Dreno B, Corvest M, Lefrancois P, Taieb C H.  A national survey of quality of life in patients with psoriasis.  JEADV 2003; 17 (Suppl 3): 59.

75.  Salonen S H (on behalf of EUROPSO Patient Survey Study Group)  Second phase of large-scale European psoriasis patient quality of life survey.  JEADV 2003; 17 (Suppl 3): 139.

76.  Myon E, Taieb C.  Psoriasis and quality of life:  SPOT study, results at 3 months.  Quality of Life Research 2003; 12: 778.

77.  Delmolino J M, Myon E, Taieb C.  Psoriasis and quality of life Spanish results.  Quality of Life Research 2003; 12: 778.

78.  Salek M S, Finlay A Y, Lewis J J C, Sumner M I.  Quality of life improves in treatment of psoriasis with intermittent short course cyclosporin (Neoral®).  Quality of  Life Research 2004; 13: 91-95.

79.  Zachariae R, Zachariae H, Blomquist K, Davidsson S, Molin L, Morl Sigurgeirsson B.  Self-reported stress reactivity and psoriasis-related stress of Nordic psoriasis sufferers.  J Eur Acad Dermatol Venereol 2004; 18(1): 27-36.

80.  Myon E, Finlay A Y, Taïeb C. Psoriasis and quality of life:  SPOT study, results at 3 months.  J Am Acad Dermatol 2004; 50 (3): P150.

81.  Gelfand J M, Feldman S R, Stern R S, Thomas J, Rolstad T, Margolis D J.  Patients with more extensive psoriasis have greater reductions in quality of life:  female patients and young patients are affected to a greater extent.  JID 2004; 122: A60.

82.  de Korte J, Sprangers M A G, Mombers F M C, Bos J D. Quality of life in patients with psoriasis: a systematic literature review.  J Investig Dermatol Symp Proc 2004; 9(2):140-147.

83.  Salonen S-H, van de Kerkhof P.  Large-scale European survey of quality of life in patients with psoriasis:  results of the second phase.  JEADV 2004; 18 (Suppl 1): 91.

84.  Sampogna F, Sera F, Abeni D; IDI Multipurpose psoriasis research on vital experience (IMPROVE) investigators.  Measure of clinical severity, quality of life, and psychological distress in patients with psoriasis:  a cluster analysis.  J Invest Dermatol 2004; 122 (3): 602-607.

85.  MullerF M, McClullagh, Fleming C J.  Prospective evaluation of the impact of a nurse-lead clinic on patients with psoriasis.  .  BJD 2004; 151 (Suppl 68): 51.

86.  Lewis V J, Finlay A Y.  Two decades’ experience of the Psoriasis Disability Index.  BJD 2004; 151 (Suppl 68):50.

87.  Smit J V, Franssen M E J, de Jong E M G J, Lambert J, Roseeuw D I, De Weert J, Yocum R C, Stevens V J, van De Kerkhof P C M.  A phase II multi-centre clinical trial of systemic bexartotene in psoriasis.  J Am Acad Dermatol 2004; 51(2): 249-256.

88.  Van de Kerkhof P C M.  The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet ®/Dovobet ®) on the quality of life in patients with psoriasis vulgaris:  a randomized controlled trial.  BJD 2004; 151: 663-668.

89.  Gelfand J M, Feldman S R, Stern R S, Thomas J, Rolstad T, Margois D J.  Determinants of quality of life in patients with psoriasis:  A study from the US population.  J Am Acad Dermatol 2004; 51 (5):  704-708.

90.  Taieb C, Finlay A Y, Myon E, Del Molino J.  Psoriasis and quality of life Spanish results.  JEADV 2004; 18: 775.

91.  Taieb C, Finlay A Y, Myon E.  Duration of psoriasis and quality of life.  JEADV 2004; 18: 775.

92.  Salonen S H.  The EUROPSO psoriasis patient survey:  second-phase results on quality of life, treatment and satisfaction.  JEADV 2004; 18: 775.

93.  Taieb C, Finlay A Y, Myon E.  Psoriasis: quality of life according to gender.  JEADV 2004; 18: 786.

94.  Taieb C, Myon E.  Psoriasis cross-description of French and Spanish patients’ quality of life.  JEADV 2004; 18: 786.

95.  Bordas X, Vanaclocha F, Puig L, Daudén E, Hernanz J, Ferrandiz C.  Quality of life in psoriatic patients treated with cyclosporine.  JEADV 2004; 18: 797.

96.  Vašků V, Semrádová V, Slonková V, Balaštík D.  Quality of life in patients with psoriasis vulgaris.  JEADV 2004; 18 (Suppl 2) 350.

97.  Salonen S-H on behalf of the EUROPSO Patient Survey Study Group.  EUROPSO quality of life and satisfaction with treatment patients survey.  Results from 26 931 members of European psoriasis patient associations.  JEADV 2004; 18 (Suppl 2) 344.

98.  Ragab N, Khafagy A, Abdallah.  Efficacy of narrow band ultraviolet-B phototherapy on improving psoriasis areas and severity index ‘PSAI’ in relation to quality of life in psoriatic patients.  JEADV 2004; 18 (Suppl 2) 331.

99.  de Korte J.  How to improve the quality of life of patients with psoriasis?  JEADV 2004; 18 (Suppl 2) 60.

100.     Fortune D G, Richards H L, Kirby B, McElhone K, Main C J, Griffiths C E M.  Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patient’s well-being.  BJD 2004; 151: 1219.

101.     Jankowiak B, Krajewska-Kulak E, Van Damme-Ostapowicz K, Wronska I, Lukaszuk C, Niczyporuk W, Baranowska A.  The need for health education among patients with psoriasis.  Dermatol Nurs 2004; 16(5): 439-44

102.     Nijsten T, Margolis D J, Feldman S R, Rolstad T, Stern R S.  Traditional systemic treatments have not fully met the needs of psoriasis patients:  Results from a national survey.  J Am Acad Dermatol 2005; 52(3): 434-444.

103.     Schmid-Ott G, Malewski P, Kreiselmaier I, Mrowietz U.  Psychosocial consequences of psoriasis - an empirical study on the burden of skin disease in 3753 patients.  Hautarzt 2005; 56(5): 466-472.

104.          Davidson S, Blomquist K, Molin L, Sigurgeirsson B, Zachariae H, Zachariae R.  Lifestyle Nordic people with psoriasis. Int J Dermatol 2005; 44(5): 378-383.

105.     Lewis V J, Finlay A Y.  Two decades’ experience of the Psoriasis Disability Index.  Dermatology 2005; 210: 261-268.

106.     Cusack C, Anwar W, Buckley C.  Effect of psychological stress reduction techniques on rate of skin clearing in patients with psoriasis receiving phototherapy/photochemotherapy.  BJD 2005; 153 (Suppl 1): 96.

107.     Prins M, Krabbe P F M, Swinkles Q O J, de Boo T, van de Kerkhof P C M.  The effect of treatment on quality of life in psoriasis patients.  Acta Derm Venerol 2005; 85: 304-310.

108.     Nijsten T, Whalley D, Gelfand J, Margolis D, McKenna S P, Stern R S.  The psychometric properties of the Psoriasis Disability Index in Untied States patients.  JID 2005; 125(4) 665-672.

109.     Yang Y, Koh D, Nyunt S Z, Ng V, Goh C L.  The psoriasis disability index in Chinese patients:  contribution of clinical and psychological variables.  International Journal of Dermatol 2005; 44: 925-929.

110.     Jankowiak B, Krajewska-Kulak E, Baranowska A, Krajewska K, Rolka H, Sierakowska M,  Ostapowicz Van Damme K, Niczyporuk W, Lewko J.  The importance of the health education in life quality improvement in patients with psoriasis.  Rocz Akad Med Bialymst 2005; 40 (Suppl1) 145-147.

111.     Sampogna F, Chren M M, Melchi C F, Taboli S, & The Italian Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Study Group.  Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis.  BJD 2006; 154: 325-331.

112.     Dubertret L, Mrowietz U, Ranki A, van de Kerkhof P C M, Chimentis S, Lotti T, Schafer G on behalf of the EUROPSO patient survey.  European patient perspectives on the impact of psoriasis, the EUROPSO patient membership survey.  Br J Dermatol 2006; 155: 729-736.

113.     Msika P.  New natural PPAR-a agonist for childhood atopic dermatitis:  Dermocorti-coid-sparing and quality of life improvement.  J am Acad Dermatol 2007; February AB67.

114.     Samoonga F, Gisondi P, Tabolli S, Abeni D & the IDI Multipurpose Psoriasis Research on Vital Experiences investigators.  Impairment of sexual life in patients with psoriasis.  Dermatology 2007; 214:144-150 

115.     Eghlileb A M, Davies E E G, Finlay AY.  Psoriasis has a major secondary impact on the lives of family members and partners.  Br J Dermatol 2007; 156: 1245.

116.     Eghlileb A M, Finlay A Y.  Assessment of patients’ psoriasis severity by relatives and partners.  JEADV 2007; 21 (Suppl 1): 30.

117.     Fukuchi O, Ito T, Hasegawa T, Nakagawa H.  The clinical usefulness of the Japanese version of the Psoriasis Disability Index in patients with psoriasis.  JEADV 2007; 21
(Suppl 1):  30. 

118.     Aghaei S, Ardekani G S.  Impact of psoriasis on quality of life in Iran.  JEADV 2007; 21 (Suppl 1): 32.

119.     Nemcova A, Kovandova D, Hercogova J, Schmiedbergerova R.  Quality of life in patients with chronic psoriasis.  JEADV 2007; 21 (Suppl 1):  33.

120.     Papoutsaki M, Chimenti M S, Costanzo A, Talamonti M, Zangrilli A, Giuta A, Bianchi L, Chimenti S.  Adalimumab for severe psoriasis and psoriatic arthritis:  an open label study in 30 patients previously treated with other biologics.  JEADV 2007; 21 (Suppl 1): 55.
J Am Acad Dermatol 2007; 56(2):269-275.

121.     Shamsuidin N, Le C S, Hussein S H.  Quality of life assessment in patients with psoriasis at    Hospital Kula Lumpur.  Investig Dermatol 2007, 127: 1809.

122.     Aghaei S.  Impact of psoriasis on quality of life in Iran.  Quality of Life Research 2007 (Supl).

123.     García-Diez A, Foraster C F, Sebstián F V, Tudela L L, Llach X B, Fernandez G S.  What characterizes the severity of psoriasis?  Dermatology 2008; 216:137-151.

124.     Ferrándiz C, García-Diez A, Lizán T L, Bermúdez-Rey L, Badia L X.  Impacto de la psoriasis en la calidad de vida repacionada con la salud.  Med Clin (Barc)  2007; 128: 325-329.